Allogeneic hematopoietic stem cell transplantation in ...
Recommend Documents
days out of the hospital between day 1 and 100 (Table). Group 2 vi- ruses were ... Conclusion: One in 4 patients was infected with a respiratory virus before HCT.
Campath anti-CD52 antibody may reduce GvHD by targeting lym- phocytes and dendritic cells. Studies with high doses (100 mg) of the humanized Campath1H ...
received total body irradiation plus cyclophoas- phamide, 8 received thiotepa 15 mg/kg plus a standard dose of cyclophoasphamide, with the addition of mel-.
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for patients with hematologic malignancies, some inherited metabolic disorders and bone ...
Allogeneic Hematopoietic Stem Cell Transplantation. Using Reduced-Intensity Conditioning for Adult T Cell. Leukemia/Lymphoma: Impact of Antithymocyte.
fludarabine-based conditioning regimen using a low dose of rabbit. ATG (Thymoglobulin) with fludarabine and intravenous busulfan has been used at The ...
Seventeen cases (age at onset, 1 month to 18 years; M/F,. 9/8) of hemophagocytic syndrome which received allo- geneic hematopoietic stem cell transplantation ...
Medical Center; 10Kobe University School of Medicine; 11Saga Prefectural Kouseikan ... Correspondence: Dr S Imashuku, Children's Research Hospital, Kyoto.
Despite major advances in the understand- ing of the molecular pathogenesis of myelo- fibrosis and the development of Janus kinase. (JAK) 1/2 inhibitors as ...
Jun 26, 2006 - Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic ...
Objective Fludarabine plus melphalan (FM) and fludarabine plus busulfan (FB) are two major conditioning regimens for allogeneic hematopoietic stem cell ...
Allogeneic hematopoietic stem cell transplant (HSCT) recipients were assessed to elucidate memory B cell defects underlying their increased susceptibility to ...
Switzerland; and 2Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, ... ciency by nonmyeloablative hematopoietic stem cell ... Correspondence: Dr T Gu¨ngo¨r, Division of Immunology, Hematology,.
Previously published data from our institution has shown excellent overall survival and low rates of GVHD at one year with alemtuzumab-based RIC-HSCT.
Jun 18, 2012 - ... Japan; 5Department of Hematology, Kanagawa Cancer Center, Yokohama, ... University Hospital, Sapporo, Japan; 16Osaka Medical Center and ... Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for se- lected hematological malignancies. Its curative potential is ...
1Division of Hematology and Cellular Therapies Unit 'Carlo Melzi', Dept. of Morphological and Medical Research, ... Locasciulli Anna (S.Camillo-Forlanini.
to be a high incidence of early (SCT day+30) mixed chimerism, yet ..... were treated with escalating doses of CPX-351 starting at 60 mg/m2 on days - 28, -26 and ...
BMT from an unrelated donor (UBMT) vs. cord blood transplantation from an unrelated donor (UCBT)], con- ditioning regimen (MAC vs. RIC), and year of HCT ...
Fred Hutchinson Cancer Research Center and the University of Washington,. Seattle, WA, USA ...... Baron F, Petersdorf EW, Gooley T, et al. What is the role for ...
Nov 24, 2005 - with active disease, ineligible for standard myeloablation, could tolerate modified .... by high-resolution class I and class II HLA typing, three had 1 allele mismatch (A,B,C- one .... of 22 months (range, 2â64), 63 patients are ali
Abstract. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain ...
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ELDERLY. PREDICTING THE RISK FOR NON RELAPSE MORTALITY. MARIANO ...
Allogeneic hematopoietic stem cell transplantation in ...
